Midatech Pharma US Inc. Watch

from 8-K 11 pages Underwriting agreement

from S-1/A 9 pages Placement Agent Agreement

from S-1/A 9 pages This Letter (The “Agreement”) Constitutes the Agreement Between Ladenburg Thalmann & Co., Inc. (“Ladenburg” or the “Placement Agent”) and DARA Biosciences, Inc. (The “Company”), That Ladenburg Shall Serve as the Exclusive Placement Agent for the Company, on a “Reasonable Best Efforts” Basis, in Connection With the Proposed Placement (The “Placement”) of (I) Registered Shares (The “Shares”) of the Company’s Common Stock, Par Value $0.01 Per Share (The “Common Stock”), and (II) Registered Warrants (The “Warrants”) to Purchase Shares of Common Stock (The “Warrant Shares” And, Together With the Common Stock and the Warrants, the “Securities”). the Terms of the Placement and the Securities Shall Be Mutually Agreed Upon by the Company and the Purchasers (Each, a “Purchaser” and Collectively, the “Purchasers”) and Nothing Herein Constitutes That Ladenburg Would Have the Power or Authority to Bind the Company or Any Purchaser or an Obligation for the Company to Issue Any Securities or Complete the Placement. This Agreement and the Documents Executed and Delivered by the Company and the Purchasers in Connection With the Placement Shall Be Collectively Referred to Herein as the “Transaction Documents.” the Date of the Closing of the Placement Shall Be Referred to Herein as the “Closing Date.” the Company Expressly Acknowledges and Agrees That Ladenburg’s Obligations Hereunder Are on a Reasonable Best Efforts Basis Only and That the Execution of This Agreement Does Not Constitute a Commitment by Ladenburg to Purchase the Securities and Does Not Ensure the Successful Placement of the Securities or Any Portion Thereof or the Success of Ladenburg With Respect to Securing Any Other Financing on Behalf of the Company. the Placement Agent May Retain Other Brokers or Dealers to Act as Sub-Agents or Selected-Dealers on Its Behalf in Connection With the Placement

from 8-K 8 pages This Letter (The “Agreement”) Constitutes the Agreement Between Ladenburg Thalmann & Co., Inc. (“Ladenburg” or the “Placement Agent”) and DARA Biosciences, Inc. (The “Company”), That Ladenburg Shall Serve as the Exclusive Placement Agent for the Company, on a “Reasonable Best Efforts” Basis, in Connection With the Proposed Placement (The “Placement”) of (I) Registered Shares (The “Shares”) of the Company’s Common Stock, Par Value $0.01 Per Share (The “Common Stock”), and (II) Warrants (The “Warrants”) to Purchase Shares of Common Stock (The “Warrant Shares” And, Together With the Common Stock and the Warrants, the “Securities”). the Terms of the Placement and the Securities Shall Be Mutually Agreed Upon by the Company and the Purchasers (Each, a “Purchaser” and Collectively, the “Purchasers”) and Nothing Herein Constitutes That Ladenburg Would Have the Power or Authority to Bind the Company or Any Purchaser or an Obligation for the Company to Issue Any Securities or Complete the Placement. This Agreement and the Documents Executed and Delivered by the Company and the Purchasers in Connection With the Placement Shall Be Collectively Referred to Herein as the “Transaction Documents.” the Date of the Closing of the Placement Shall Be Referred to Herein as the “Closing Date.” the Company Expressly Acknowledges and Agrees That Ladenburg’s Obligations Hereunder Are on a Reasonable Best Efforts Basis Only and That the Execution of This Agreement Does Not Constitute a Commitment by Ladenburg to Purchase the Securities and Does Not Ensure the Successful Placement of the Securities or Any Portion Thereof or the Success of Ladenburg With Respect to Securing Any Other Financing on Behalf of the Company. the Placement Agent May Retain Other Brokers or Dealers to Act as Sub-Agents or Selected-Dealers on Its Behalf in Connection With the Placement

from 8-K 7 pages This Letter (The “Agreement”) Constitutes the Agreement Between Ladenburg Thalmann & Co., Inc. (“Ladenburg” or the “Placement Agent”) and DARA Biosciences, Inc. (The “Company”), That Ladenburg Shall Serve as the Exclusive Placement Agent for the Company, on a “Reasonable Best Efforts” Basis, in Connection With the Proposed Placement (The “Placement”) of (I) Registered Shares (The “Shares”) of the Company’s Common Stock, Par Value $0.01 Per Share (The “Common Stock”), and (II) Warrants (The “Warrants”) to Purchase Shares of Common Stock (The “Warrant Shares” And, Together With the Common Stock and the Warrants, the “Securities”). the Terms of the Placement and the Securities Shall Be Mutually Agreed Upon by the Company and the Purchasers (Each, a “Purchaser” and Collectively, the “Purchasers”) and Nothing Herein Constitutes That Ladenburg Would Have the Power or Authority to Bind the Company or Any Purchaser or an Obligation for the Company to Issue Any Securities or Complete the Placement. This Agreement and the Documents Executed and Delivered by the Company and the Purchasers in Connection With the Placement Shall Be Collectively Referred to Herein as the “Transaction Documents.” the Date of the Closing of the Placement Shall Be Referred to Herein as the “Closing Date.” the Company Expressly Acknowledges and Agrees That Ladenburg’s Obligations Hereunder Are on a Reasonable Best Efforts Basis Only and That the Execution of This Agreement Does Not Constitute a Commitment by Ladenburg to Purchase the Securities and Does Not Ensure the Successful Placement of the Securities or Any Portion Thereof or the Success of Ladenburg With Respect to Securing Any Other Financing on Behalf of the Company. the Placement Agent May Retain Other Brokers or Dealers to Act as Sub-Agents or Selected-Dealers on Its Behalf in Connection With the Placement

from 8-K 44 pages DARA Biosciences, Inc. Up to $2,730,000 of Common Stock (Par Value $0.01 Per Share) At-The-Market Sales Agreement

from 8-K 42 pages Securities Purchase Agreement

from 8-K 17 pages Confidential Donald Kiepert Jr., President & Chief Executive Officer Point Therapeutics, Inc. 155 Federal Street Boston, Ma 02110 Dear Mr. Kiepert

from 8-K 32 pages 8,050,000 Shares of Common Stock Point Therapeutics, Inc. (A Delaware Corporation) Common Stock Underwriting Agreement

from S-1 10 pages Point Therapeutics, Inc. Warrant for the Purchase of Shares of Common Stock

from S-1 9 pages Point Therapeutics, Inc. Warrant for the Purchase of Shares of Common Stock

from S-1 36 pages Subscription Agreement

from S-1 8 pages Engagement Agreement